• Thurs news: Amgen reaps Horizon buyout rewards in Q3. Baxter exits China IV market. Big Pharma earnings. Novo takes steps to end shortages. Roche Alzheimer’s test. See more on our front page


FlexHD





How do you guys feel about FlexHD ? I've heard mixed reports. I know we can make a lot of $, but a lot of people are saying this is a bad product.

I sold a lot of it before it was taken out of the CSR bag. Good product with no support. No clinicals, not much in the way of prof-ed. Lifecell has done a fantastic job marketing Alloderm and Stratice. In my market they have local profed dinners all the time.

But it only takes converting a few marginally busy plastic surgeons to make some good money on the product. Remember, a bilateral breast recon is an 8-10K case. Look for the busy plastics in outlying hospitals who may not have been to ten lifecell dinners over the last year.

If you're an HSR looking for use in abdominal, good luck. That's an uphill battle.